Takeda's immune disease drug meets main goal of mid-to-late stage trial

ReutersMay 4, 2026 12:11 PM

View all comments（0）



May 4 (Reuters) - Takeda Pharmaceutical 4502.T said its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a mid- to late-stage clinical trial.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Japan and South Korea Stocks Rise in Early Trade, Samsung Rebounds Over 3%, Trump Arrives in Beijing With Tech Giants

TradingKey - Asian stock markets generally trended higher in Thursday morning trading. The Nikkei 225 opened 0.14% higher, with intraday gains expanding to 200 points at one stage, while SoftBank Group tracked the advance with a gain of over 1%. South Korea’s KOSPI opened 0.4% higher and rallied quickly, with intraday gains reaching 1% and surpassing the 7,900-point mark. LG Electronics led the index constituents, rising more than 5%.

Anthropic in Talks for Massive $30 Billion Funding, Valuation May Join Trillion-Dollar Ranks

TradingKey - On May 12, Eastern Time, Bloomberg reported that AI startup Anthropic is in preliminary discussions with investors to raise at least $30 billion in new capital at a pre-money valuation exceeding $900 billion. If the deal is finalized, it would mark the company's largest funding round to

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

TradingKey - During the Asian trading session on May 11, SK Hynix shares rose by more than 15% at one point, hitting an all-time intraday high of 1.949 million KRW, with its market capitalization surpassing $900 billion. The year-to-date cumulative gain is approximately 197.03%, with the share price nearly tripling.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools